Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3Expanded_access 2

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Colorectal Neoplasms 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × leronlimab × Clear all
NCT06699836 2026-05-18

CLOVER

CytoDyn, Inc.

Phase 2 Active not recruiting
66 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04504942 2026-01-23

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

CytoDyn, Inc.

Phase 2 Completed
16 enrolled 16 charts
Other solid neoplasm

Solid Tumor, Adult

NCT03838367 2025-09-09

Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC

CytoDyn, Inc.

Phase 1/2 Terminated
10 enrolled 15 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡